| Anticancer Fund

On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients

Ciska Verbaanderd, Ilse Rooman, Lydie Meheus, Isabelle Huys - On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients. Frontiers in Pharmacology, 31 January 2020, DOI: 10.3389/fphar.2019.01664

Mon, 02/03/2020 - 12:00

Transparancy of clinical trial reports assured

Wed, 01/22/2020 - 12:00

Clinical trials should remain transparent

Tue, 01/21/2020 - 12:00

Biased by design? Clinical trials and patient benefit in oncology

Pan Pantziarka, Ciska Verbaanderd, Lydie Meheus - Biased by design? Clinical trials and patient benefit in oncology. Future Medicine, 16 (3), doi.org/10.2217/fon-2019-0763

Tue, 01/14/2020 - 12:00

The Anticancer Fund’s recommendations to Horizon Europe

Wed, 12/18/2019 - 12:00

Launch of a Call for Research Proposal

Tue, 12/17/2019 - 12:00

Low-dose azacytidine, pioglitazone and retinoic acid in ≥ 60 years patients with acute myeloid leukaemia refractory to chemotherapy (AML-ViVA)

Presented on the 61st ASH Annual Meeting & Exposition

Mon, 12/09/2019 - 12:00

Intraoperative ketorolac in High-Risk Breast Cancer Patients. A Prospective, Randomized, Placebo-Controlled Clinical Trial.

Patrice Forget, Gauthier Bouche, Francois P. Duhoux, Pierre G. Coulie,Jan Decloedt, Alain Dekleermaker, Jean-Edouard Guillaume, Marc Ledent, Jean- Pascal Machiels, Véronique Mustin, Walter Swinnen, Aline van Maanen, Lionel Vander Essen, Jean-Christophe Verougstraete, Marc De Kock, Martine Berliere (2019) - Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PLoS ONE 14(12): e0225748. https://doi.org/10.1371/journal.pone.0225748

Thu, 12/05/2019 - 12:00